ExeGi Pharma Positive Topline Results in EXE-346 PROF Phase 1b Study

PROF study demonstrates safety of EXE-346 drug product in pouch anastomosis patients at 3,000 billion live probiotic consumption per day for four weeks Excessive bowel movement (BM) frequency was reduced at four weeks by 18% over baseline values ROCKVILLE, Md., Dec. 17, 2024 /PRNewswire/…